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Introduction {#sec1}
============

The prostatic gland contains basal and luminal epithelial cells, together with rare neuroendocrine cells. Luminal cells express cytokeratin (CK) 18 and androgen receptor (AR) and are androgen dependent, whereas basal cells express CK5 and stem cell (SC) transcription factor p63 and are androgen independent ([@bib31]). Developmentally, the murine prostate originates from an ancestral p63^+^AR^−^ basal SC population ([@bib23]). Studies using prostate regeneration assays demonstrate that multipotent SCs capable of differentiating into all prostatic cell types are localized in the basal layer ([@bib13]). Therefore, basal cells are thought to represent the main pool of prostate stem cells (PSCs) ([@bib44]). However, lineage-tracing studies indicate that basal cells rarely generate luminal cells during adult tissue homeostasis but display plasticity under the inductive influence of embryonic urogenital mesenchyme (UGM) cells in tissue regeneration assays, acquiring facultative stem/progenitor cell properties and generating luminal cells ([@bib4], [@bib44]). Consequently, both cell layers in adult murine prostate are self-sustained by lineage-restricted stem/progenitor cells ([@bib4]), although more primitive SCs reside in the basal layer ([@bib22]). An *in vitro* organoid assay recently identified a small fraction (\<1%) of luminal cells functionally defined as multipotent luminal progenitors in that they were able to generate organoids containing both basal and luminal cells ([@bib9]). Beyond homeostasis, several rare luminal progenitor populations have been reported in regressed mouse prostates, including castration-resistant NKX3.1-expressing (CARN) ([@bib42]), SCA-1^+^ ([@bib15]), and castration-resistant BMI1-expressing (CARB) ([@bib49]) cells. The precise relationship between these luminal progenitor cell populations remains unclear.

The prostate has been a model for studying tissue SCs, because it undergoes atrophy upon castration and regeneration upon re-administration of androgen, and this regression-regeneration cycle can be repeated multiple times. Somatic SCs are generally dormant and this cardinal slow-cycling feature is frequently utilized to identify putative SCs by labels that become diluted as a result of cell division ([@bib36]). Studies have shown that label-retaining cells (LRCs) in many organs are enriched for SCs ([@bib6], [@bib7], [@bib35], [@bib37], [@bib38], [@bib43]). Previously, 5-bromodeoxyuridine (BrdU) was employed to perform pulse-chase experiments to identify candidate SCs. In the prostate, a long-term chased BrdU^+^ cell population, encompassing both basal and luminal cells, which resides in the proximal region of mouse prostatic ducts and exhibits attributes of epithelial SCs was proposed as PSCs ([@bib37]). Whether these dormant cells truly represent SCs has not been answered mainly due to the technical infeasibility of purifying out live BrdU^+^ cells for functional studies. More recently, cell surface markers coupled with fluorescence-activated cell sorting (FACS) have been used to dissect the subsets of cells within a bulk population. These assays depend on known SC markers, and, notably, the majority of widely used markers (e.g., SCA-1, CD49f) preferentially identify prostate basal stem-like cells ([@bib17], [@bib19], [@bib32], [@bib48]), leaving the luminal cell compartment under-studied. Lineage-tracing technology has greatly enhanced our understanding of SC development; however, lineage-tracing studies only suggest that a certain cell population harbors SCs, but could not pinpoint which precise cell(s) within the population is SC ([@bib26]).

In this study, we employed a bigenic mouse model to identify, isolate, and characterize the stem-like properties and gene expression profiles of quiescent LRCs from mouse prostates expressing a tunable H2B-GFP driven by the promoter of a luminal lineage-preferential gene *probasin* ([@bib34]). Biological and molecular studies show that long-term chased luminal LRCs are inherently resistant to castration and can generate organoids *in vitro* and prostatic glands *in vivo*. Notably, the LRC-derived organoids and prostatic glands contain both basal and luminal cells, suggesting the bipotency of LRCs. RNA sequencing (RNA-seq) analysis of this rare population reveals a progenitor-like transcriptome that resembles therapy-resistant prostate cancer (PCa). Analysis of a spectrum of phenotypic markers previously linked to epithelial cell stemness reveals heterogeneity in luminal progenitor populations. Collectively, our study augments our understanding of prostate luminal progenitors and provides valuable insights into their potential roles in prostate development and, possibly, cancer initiation and progression.

Results {#sec2}
=======

Establishing a Bigenic Mouse Model to Label Slow-Cycling Cells in Prostatic Epithelium {#sec2.1}
--------------------------------------------------------------------------------------

To study the dormant cell population in the luminal cell compartment, we adopted a Tet-Off system similar to that described previously ([@bib38]) by engineering a Pb-tetVP16 transgenic line to express tetracycline repressor-VP16 controlled by *probasin* (*Pbsn*)-based *ARR2Pb* promoter ([@bib50]; [Figure S1](#mmc1){ref-type="supplementary-material"}A). By crossing the Pb-tetVP16 mice with the tetracycline-responsive element-regulated mCMV/H2B-GFP reporter mice ([@bib38]), we generated the bigenic mice, Pb-tetVP16-GFP, in which GFP expression is ultimately driven by *Pbsn* promoter ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). In this way, without doxycycline (DOX) administration (pulse), the prostate tissues would be largely GFP^+^. Upon DOX administration (chase), the prostate will gradually lose the GFP signal due to cell division, while infrequently cycling and dormant cells would retain GFP for an extended period of time ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Indeed, the whole prostate or microdissected prostate branches from the unchased young adult (6 weeks) animals were green, and GFP intensity dropped accordingly at different intervals of chase ([Figure 1](#fig1){ref-type="fig"}A). These data demonstrate the successful establishment of a bigenic mouse model to fluorescently label slow-cycling cells in the prostatic epithelium.Figure 1Identification of H2B-GFP LRCs(A) Loss of GFP signals in DOX-chased prostates. Shown are gross GFP images in whole-mount prostates (left) and microdissected prostate branches (right) isolated from bigenic mice chased for 0 weeks (no chase), 6 weeks, and 9 weeks.(B) Gross GFP images in different lobes of prostates dissected from unchased adult Pb-tetVP16-GFP bigenic mice.(C--E) Double IF of CK5 or CK8 and GFP in different prostate lobes harvested from bigenic mice chased (on DOX diet) for 0 weeks (C), 9 weeks (D), and 12 weeks (E). Arrows and dashed arrows in (C) (top) indicate CK5^+^GFP^+^ basal cells and luminal cells shed into the lumen, respectively. AP, VP, DP, and LP refer to anterior, ventral, dorsal, and lateral prostate lobes, respectively. Dashed boxed regions are enlarged (solid boxes). Scale bars, 50 μm.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

H2B-GFP Primarily Labels Prostate Luminal Cells {#sec2.2}
-----------------------------------------------

We assessed the expression and distribution of GFP^+^ cells in the adult prostate glands. Consistent with the reported activity of endogenous *Pbsn* promoter ([@bib50]), GFP signal was higher in ventral prostate (VP) and dorsal and lateral prostate (DLP) than that in anterior prostate (AP) ([Figure 1](#fig1){ref-type="fig"}B). As a marker of differentiation and androgen action in the mouse prostate, Pbsn is primarily expressed in the luminal epithelial cells. Double immunofluorescence (IF) staining of CK5 or CK8 and GFP indicated that, as expected, GFP^+^ cells were mainly localized to the luminal compartment in unchased prostates ([Figure 1](#fig1){ref-type="fig"}C). Consistent with the varying gross GFP intensity in different prostate lobes ([Figure 1](#fig1){ref-type="fig"}B), the frequency of GFP^+^ cells was much higher in VP (79.4%) and DLP (79.4%) than that in AP (43.8%) ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). We also observed some GFP^+^CK5^+^ double-positive cells ([Figure 1](#fig1){ref-type="fig"}C, solid arrows) and non-epithelial GFP^+^ cells in the stromal compartment ([Figure S1](#mmc1){ref-type="supplementary-material"}C), suggesting that the *Pbsn* promoter is also active in a small subset of basal and stromal cells, as reported previously ([@bib39], [@bib41]). Interestingly, during the course of this work and consistent with a prior study ([@bib45]), we frequently noticed many GFP^+^ luminal cells in the lumen ([Figure 1](#fig1){ref-type="fig"}C, dashed arrows), implying that luminal cells have a faster turnover than basal cells (see below).

Kinetics of H2B-GFP LRCs in Basal and Luminal Cell Layers {#sec2.3}
---------------------------------------------------------

To characterize optimal chase time and kinetic changes in GFP^+^ cells, we quantified the percentage of GFP^+^ cells at different time points after chase according to their lineage identity ([Figures 1](#fig1){ref-type="fig"}C--1E and [2](#fig2){ref-type="fig"}A). We started chasing the male mice at 6--8 weeks when the prostate is generally well developed. The initial luminal cell-labeling efficacy was 79.4%, 79.4%, and 43.8% for VP, DLP, and AP, respectively ([Table S1](#mmc2){ref-type="supplementary-material"}). As expected, upon chase, prostatic cells gradually lost GFP signal ([Figures 2](#fig2){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). By 9-week chase, the percentage of GFP^+^ luminal cells dropped from ∼80% to \<20% in VP, and by 14-week chase and after, GFP^+^ cells were rarely seen ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}A). After a 12-week chase, the luminal GFP^+^ cells remained at 2%--6% in different lobes ([Figure 2](#fig2){ref-type="fig"}C). Consequently, we referred to the GFP^+^ cells that persisted for at least a 12-week chase as LRCs. This time point is in line with studies in other organs using similar H2B-GFP mouse models ([@bib6], [@bib35], [@bib43]). Our model also labeled a small subset of CK5^+^ basal cells, with 2%--8% GFP^+^ cells in unchased lobes and 1%--3% GFP^+^ cells after a 12-week chase ([Figure 2](#fig2){ref-type="fig"}D; [Table S1](#mmc2){ref-type="supplementary-material"}). Interestingly, compared with the relatively flat curve of basal GFP^+^ cell kinetics, luminal GFP^+^ cells decreased much faster as a function of chase ([Figures 2](#fig2){ref-type="fig"}C and 2D). IF analysis revealed Ki-67^+^ cells exclusively in luminal layer in all lobes ([Figure 2](#fig2){ref-type="fig"}E). Furthermore, we frequently and exclusively observed symmetrically dividing GFP^+^ cells in the luminal layer ([Figure 2](#fig2){ref-type="fig"}F). These observations validated faster proliferation and loss of GFP signal in luminal cells compared with basal cells. Quantitatively, unchased young adult bigenic mice displayed a small percentage of prostatic GFP^+^ cells that co-expressed the proliferation marker Ki-67 (4.03%, 0.42%, and 1.80% for AP, VP, and DLP, respectively); in contrast, after a 12-week chase no GFP^+^ cells were stained positive for Ki-67 ([Figures 2](#fig2){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}B), confirming the quiescence of LRCs.Figure 2Dynamics and Characterization of LRCs(A) Scheme for tracking the dynamics of prostatic GFP^+^ cells in hormonally intact mice, in which we started chasing the bigenic animals at 6 weeks of age and analyzed the prostate tissues at different time points post chase.(B) IF images of CK8 and GFP in the VP isolated from bigenic mice chased for different time intervals.(C and D) Quantification of GFP^+^ cells in luminal (C) and basal (D) cell populations as a function of chase time. At each time point, two to four mice were examined, and data are shown as the mean ± SE.(E) IF staining of Ki67 and CK8 in different prostate lobes in wild-type adult mice. Arrows indicate Ki67^+^CK8^+^ cells.(F) IF of GFP and CK8 in the AP of unchased adult bigenic mice showing symmetrical division of luminal cells.(G) IF staining of Ki67 and GFP in the VP of bigenic mice chased for 12 weeks.See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Luminal LRCs Are Enriched in the Proximal Prostatic Ducts and Mark Progenitors Capable of Regenerating Prostate Glands *In Vivo* {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------

We next performed *in vitro* and *in vivo* SC-related assays, first in bulk GFP^+^ LRCs. The lineage-negative (Lin^−^) GFP^+^ cells freshly purified from the prostates chased for 12 weeks ([Figure S3](#mmc1){ref-type="supplementary-material"}A) displayed higher capacity to form 2D colonies and 3D spheres with larger size ([Figures 3](#fig3){ref-type="fig"}A--3C) than matched GFP^−^ cells. *In vivo* tissue regeneration assays demonstrated that both GFP^+^ and GFP^−^ cells could readily regenerate prostate glandular structures with secretions in the lumen ([Figure 3](#fig3){ref-type="fig"}D). The origin of the recombinants was verified by GFP signal and staining ([Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}B). It is worth noting that, after a 12-week chase, the LRCs were composed of both luminal and basal cells (ratio = 2:1; [Table S1](#mmc2){ref-type="supplementary-material"}). As basal cells represent the main PSC pool, it is expected that GFP^−^ population, which contained the majority of both luminal and basal cells, would also efficiently regenerate prostate tissues *in vivo*. Regardless, our data indicate that the long-term chased LRC population harbors stem/progenitor cells with tissue regeneration ability *in vivo*.Figure 3The LRC Population Harbors Tissue Regeneration Ability *In Vivo*Freshly purified lineage-depleted (Lin^−^) prostatic LRCs (i.e., GFP^+^ cells from 12-week-chased bigenic mice) exhibit higher stem/progenitor activities than matched non-LRCs (i.e., GFP^−^ cells). Shown are colony formation (A), limiting-dilution sphere (B), sphere size measurement (C), and *in vivo* prostate tissue regeneration (D) assays. In (D), 1, 2, and 3 indicate the three representative recombinants. Results shown for each panel were representative data of at least two to three independent experiments showing consistent results. For (B) and (C), data are shown as the mean ± SD derived from technical replicates. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

To "zoom in" on the biological differences between luminal and basal LRCs, we purified GFP^+^ cells from the two cell compartments using marker staining and FACS ([@bib39]) to identify basal (SCA-1^+^CD49f^hi^), luminal (SCA-1^−^CD49f^lo^), and stromal (SCA-1^+^CD49f^−/lo^) cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Since the *Pbsn* promoter is active in only a small subset of basal cells ([@bib39], [@bib41]), we considered our Pb-tetVP16-GFP bigenic model non-optimal to characterize basal SCs. In support, basal LRCs exhibited limited advantages over basal non-LRCs in SC-related assays, exhibiting slightly increased 2D clonal capacity and nearly equivalent sphere-forming cell frequency ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C), although GFP^+^ basal cells did form larger 3D spheres than GFP^−^ basal cells ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Overall, these results could be explained by low labeling efficiency in the basal cell layer and high SC activity of stochastic basal cells. Therefore, for the remainder of this study we focused on luminal LRCs.

Since our initial luminal cell-labeling efficacy was ∼80% for VP and DLP, we first tested whether luminal progenitor cell activity was equally distributed between the labeled and unlabeled (∼20%) luminal populations in unchased adult animals. Both 2D clonal ([Figure S4](#mmc1){ref-type="supplementary-material"}E) and 3D organoid ([Figure S4](#mmc1){ref-type="supplementary-material"}F) assays revealed similar activities in unchased luminal (L)-GFP^+^ and L-GFP^−^ cells, validating the suitability of our model in comparing stem/progenitor cell activities in chased L-GFP^+^ and L-GFP^−^ cells. Freshly purified luminal LRCs from 12-week-chased prostates exhibited significantly higher clonal and organoid-forming ([Figures 4](#fig4){ref-type="fig"}A and 4B) capacities than matched luminal GFP^−^ cells. Importantly, luminal GFP^+^ cells formed large hollow organoids, whereas only a limited number of luminal GFP^−^ cells formed small compact spheres ([Figure 4](#fig4){ref-type="fig"}C). Importantly, luminal LRC-derived organoids had a glandular structure reminiscent of normal prostate, with p63^+^ and CK5^+^ basal cells mainly residing in the peripheral layer ([Figure S4](#mmc1){ref-type="supplementary-material"}G). This result is in line with recent findings that only multipotent luminal progenitors can form organoids *in vitro* ([@bib9]). When we mixed L-GFP^+^ or L-GFP^−^ cells (4.5 × 10^3^) with mouse UGM and implanted subcutaneously into NOD-SCID-IL2Rγ^null^ (NSG) mice, only L-GFP^+^ cells generated prostatic glandular structures with overt secretions in the lumen ([Figure 4](#fig4){ref-type="fig"}D), whereas even higher numbers of luminal GFP^−^ cells (up to 18 × 10^3^) failed to give rise to prostatic tissue (not shown). These LRC-regenerated glands were normal-appearing with a layer of CK8^+^ luminal cells lining the lumen and a discontinuous layer of CK5^+^ basal cells encapsulating the structure ([Figure 4](#fig4){ref-type="fig"}E). The identity of injected cells and the LRC origin of recombinants were verified by GFP staining ([Figure 4](#fig4){ref-type="fig"}F), and the level of GFP was still detectable after several rounds of cell proliferation during prostate regeneration (not shown). These results together indicate that luminal LRCs mark luminal progenitors with bilineage differentiation capacity *in vitro* and *in vivo*.Figure 4Luminal LRCs Mark Progenitors Capable of Regenerating Prostate Glands *In Vivo*(A--C) Freshly purified Lin^−^ luminal GFP^+^ LRCs exhibit stem/progenitor activities. Shown are higher colony- (A) and organoid- (B) forming capabilities and larger sphere sizes (C) in L-GFP^+^ compared with L-GFP^−^ cells. For (B) and (C), data are shown as the mean ± SD derived from technical replicates.(D--F) Only luminal GFP^+^, but not GFP^−^ cells, are capable of regenerating prostate tissues *in vivo*. Shown are H&E staining (D) and IF of CK5 and CK8 (E), and GFP (F) in prostate glands regenerated *in vivo* from sorted luminal GFP^+^ cells co-injected with mouse UGM.(G and H) Enrichment of luminal LRCs in the proximal mouse prostate. Different prostate lobes dissected from bigenic mice at 10.5 weeks of DOX chase were divided longitudinally into two portions (distal and proximal) and subjected to IF of GFP and CK8. Shown are representative images (G) and quantification data (H) from two different mice. Results shown (A)--(F) are representative data of at least two to three independent experiments showing consistent results. For (G) and (H), two bigenic mice were analyzed and data represent the means from cell number counting of five to eight random high-magnification (×20) images of each indicated category.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

Previous studies using a BrdU label-retention strategy suggested that putative PSCs (including both basal and luminal cells) are slow cycling and enriched in the proximal region of the prostate ([@bib37]). We sought to examine whether our luminal LRCs are also enriched in the proximal prostate. Each prostate lobe from mice chased for 10.5 weeks was dissected longitudinally into two portions, representing the distal and proximal prostatic ducts. IF analysis of GFP and CK8 indicated that the GFP^+^CK8^+^ luminal LRCs were significantly enriched in the proximal prostatic ducts adjacent to the urethra ([Figures 4](#fig4){ref-type="fig"}G and 4H).

Interestingly, when we examined the mRNA and protein level of PBSN in the pelvic urogenital sinus (UGS) of newborn and 1-week-old male mice, we observed that the *Pbsn* mRNA and PBSN protein were minimally expressed in newborn (d1) UGS but readily detectable in 1-week-old UGS ([Figures S4](#mmc1){ref-type="supplementary-material"}H--S4J), suggesting that *Pbsn* is expressed early on in urogenital tissues and *Pbsn* promoter activity is not necessarily active only in mature fully differentiated luminal cells. Indeed, we detected GFP^+^ cells co-expressing CK8 and relatively high levels of PBSN protein in pelvic UGS of 1-week-old bigenic mice ([Figure S4](#mmc1){ref-type="supplementary-material"}K). These results indicate that our LRC labeling system is also suitable in marking luminal progenitor cells at early developmental stages.

Luminal LRCs Display a Luminal Progenitor Gene Expression Signature {#sec2.5}
-------------------------------------------------------------------

We next sought to determine the molecular features of L-GFP^+^ progenitors prepared from bigenic mice chased for 12 weeks. By performing genome-wide RNA-seq analysis using rRNA-depleted total RNAs ([Figure 5](#fig5){ref-type="fig"}A), we obtained an average of ∼77 million reads per sample with an average mapping rate of 93% to the reference mouse genome (UCSC version mm10; [Figure S5](#mmc1){ref-type="supplementary-material"}A). MA plot indicated appropriate normalization of our RNA-seq data ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Gene set enrichment analysis (GSEA) of RNA-seq transcriptome revealed exclusive enrichment in L-GFP^+^ (over L-GFP^−^) cells of gene signatures related to luminal epithelial progenitors and SCs ([Figure 5](#fig5){ref-type="fig"}B, plots 1--4). Significantly, a recently reported signature of an AR-deleted luminal cell population with a stem-like phenotype in the mouse prostate ([@bib47]) was significantly enriched in our luminal LRCs ([Figure 5](#fig5){ref-type="fig"}B, plot 5). Furthermore, we recently developed an *in vitro* 2D culture system that allows enrichment of luminal progenitors from primary human prostate tissues ([@bib53]). The gene signature of this cultured-enriched human luminal progenitors (WIT-L) was also enriched in luminal LRCs ([Figure 5](#fig5){ref-type="fig"}B, plot 3). In contrast, and, as expected, signatures associated with non-progenitor cells (luminal progenitor_down), AR signaling and steroid/androgen hormone metabolism were only enriched in L-GFP^−^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C). It has been suggested that luminal progenitors are less dependent on AR signaling ([@bib2], [@bib14]). Consistent with an enrichment of AR/androgen signaling in L-GFP^−^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}C) and with AR^−^ luminal cell signature ([@bib47]) in L-GFP^+^ cells ([Figure 5](#fig5){ref-type="fig"}B, plot 5), *Ar* mRNA expression was decreased in L-GFP^+^ cells ([Figure 5](#fig5){ref-type="fig"}C). IF analysis of GFP and AR using titrated anti-AR antibody dilutions revealed significant heterogeneity of AR expression within luminal cell population and indicated that ∼37% ± 1.6% of GFP^+^ luminal cells expressed low AR protein ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}D). Interestingly, CK19, a marker for luminal transit amplifying cells ([@bib8], [@bib11], [@bib40]), and CD24a, a cell surface marker frequently used to enrich mammary luminal progenitors ([@bib6], [@bib25]), were dramatically increased in L-GFP^+^ cells ([Figure 5](#fig5){ref-type="fig"}C). Intriguingly, we observed higher levels of *Pbsn* in L-GFP^+^ versus L-GFP^−^ cells ([Figure 5](#fig5){ref-type="fig"}C), perhaps indicative of the luminal nature of LRCs and also due to LRC identification by virtue of *Pbsn* promoter activities. Real-time qPCR analysis in two independently sorted biological samples confirmed slightly reduced *Ar* mRNA levels in L-GFP^+^ cells and also validated the differentially expressed patterns of about a dozen genes in L-GFP^+^ versus L-GFP^−^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}E; data not shown). Intriguingly, L-GFP^+^ cells, compared with L-GFP^−^ cells, expressed higher levels of luminal markers (*Nkx3.1, Krt8*, and *Krt18*) but lower levels of basal genes (*Trp63* and *Krt5*) ([Figure S5](#mmc1){ref-type="supplementary-material"}E).Figure 5Luminal LRCs Display a Luminal Progenitor Gene Signature Associated with CRPC(A) Scheme of RNA-seq experiments using freshly purified L-GFP^+^ and L-GFP^−^ cells from bigenic mice chased for 12 weeks.(B) Representative GSEA results in luminal GFP^+^ cells.(C) Differential expression of the indicated genes in RNA-seq in L-GFP^+^ versus L-GFP^−^ cells.(D) IF of GFP and AR in 12-week-chased animals. Shown are representative images (left) and quantification data (right; a total of 41, 71, and 73 GFP^+^ cells for AP, VP, and DLP, respectively, were counted from four to six random high-magnification (×20) images of each lobe). In (D), solid arrows point to GFP^+^/AR^hi^ cells and dashed arrows to GFP^+/^AR^low^ cells.(E) Functional annotation by DAVID of genes preferentially upregulated in luminal GFP^+^ cells.(F and G) GSEA results for the enrichment of indicated gene signatures in luminal GFP^+^ cells.See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

To further dissect the transcriptomic profiles in L-GFP^+^ cells ([Table S2](#mmc3){ref-type="supplementary-material"}), we performed the pathway/network enrichment analysis by Ingenuity Pathway Analysis and DAVID gene ontology annotation. The two approaches generated similar results and revealed neurogenesis, SC and development, inflammation/immunity, and cell adhesion being the top gene categories overrepresented in L-GFP^+^ cells ([Figures 5](#fig5){ref-type="fig"}E and [S5](#mmc1){ref-type="supplementary-material"}F). Interestingly, we have recently shown that normal human prostate basal/SCs ([@bib52]) and PSA^−/lo^ prostate cancer SCs ([@bib24]) also preferentially express many neurogenesis-related genes. Further GSEA corroborated that, compared with L-GFP^−^ cells, the slow-cycling L-GFP^+^ cells were highly enriched in gene networks involved in neural/neuronal development and functions ([Figures 5](#fig5){ref-type="fig"}B, plot 6, and S5G). Surprisingly, we observed no obvious enrichment of cell-cycle-related pathways in L-GFP^+^ cells, and a survey of key cell-cycle regulators revealed a generally decreased expression of positive cell-cycle genes, while cell-cycle-negative regulators remained unchanged ([Figure S5](#mmc1){ref-type="supplementary-material"}H). These results implicate potential involvement of other mechanisms (e.g., transforming growth factor β signaling \[[@bib28]\]) in driving the quiescence of LRCs.

Neurogenesis and Inflammation Gene Signatures Link the Gene Expression Profile in Luminal LRCs to Aggressive and Castration-Resistant PCa {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------------------------

Our recent studies ([@bib53]) linked the gene expression profile in WIT-L human prostate luminal progenitors to aggressive subtypes of PCa such as CRPC (castration-resistant PCa) and neuroendocrine PCa. Further, attenuated AR activity and androgen deprivation therapy (ADT) promote a stem-like cell phenotype in PCa ([@bib29]) and inflammation has been shown to expand a progenitor-like luminal cell pool ([@bib18]) and decrease AR signaling in human prostatic luminal cells ([@bib51]). These discussions prompted us to determine whether the gene expression profile in luminal LRCs could be linked to clinical features of PCa. GSEA revealed a significant enrichment of gene signatures of WIT-L human luminal progenitors in L-GFP^+^ cells ([Figure 5](#fig5){ref-type="fig"}B, plot 3), suggesting that the luminal LRC gene profile may associate with aggressive PCa phenotypes. In support, gene signatures in patient CRPC after failure of ADT were enriched in L-GFP^+^ cells ([Figures 5](#fig5){ref-type="fig"}F and [S5](#mmc1){ref-type="supplementary-material"}I). These latter observations may suggest a global progenitor-like gene expression profile in human CRPC.

Of interest, a gene signature of mouse prostate tumors originated from basal cells ([@bib44]) was modestly but significantly enriched in L-GFP^+^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}J), suggesting that prostate tumors with a basal cell origin may be maintained by luminal progenitor-like cells, consistent with an earlier study ([@bib33]). Importantly, a recently reported gene signature of a human CD38^low^ prostatic luminal progenitor population was dramatically enriched in our L-GFP^+^ cells ([Figure 5](#fig5){ref-type="fig"}G). Of note, the CD38^low^ human luminal progenitors are tightly associated with inflammation in PCa, express an inflammatory signature with reduced AR and androgen signaling, and associate with disease progression and poor outcome ([@bib18]). Thus, our mouse luminal LRCs share molecular features with human prostatic luminal progenitors.

Luminal LRCs Resist Castration *In Vivo* {#sec2.7}
----------------------------------------

The cellular origin(s) of castration resistance is a central question in PCa research and a long-standing hypothesis is that stem/progenitor cells may preferentially survive ADT. Consequently, we evaluated the *in vivo* castration sensitivity of luminal LRCs. To first assess whether our model could label luminal cells intrinsically resistant to castration, we castrated the unchased Pb-tetVP16-GFP male mice at 6--8 weeks and then started DOX chase and examined the abundance of GFP^+^ cells in prostate lobes at different time points after castration. Numerous GFP^+^ cells (8.0%, 29.3%, and 20.1% for AP, VP, and DLP, respectively) were observed at even 12 weeks after castration ([Figure S6](#mmc1){ref-type="supplementary-material"}A), suggesting that our model marks a proportion of luminal cells that are intrinsically castration resistant in physiological conditions. We next sought to evaluate whether long-term chased LRCs resist castration. We castrated 10- to 12-week-chased bigenic male mice and analyzed prostates 1--4 weeks later ([Figures 6](#fig6){ref-type="fig"}A--6D). As short as 1 week after castration, seminal vesicles and prostate glands shrank significantly ([Figures 6](#fig6){ref-type="fig"}A and 6C), suggesting successful androgen ablation. In all experimental settings, the frequency of luminal LRCs (GFP^+^CK8^+^) dramatically increased post castration, indicating that GFP^+^ cells possessed intrinsic survival advantages over GFP^−^ cells ([Figures 6](#fig6){ref-type="fig"}A--6D). For example, in uncastrated bigenic mice chased for 14 weeks, very few GFP^+^ cells were seen ([Figure S2](#mmc1){ref-type="supplementary-material"}A); in contrast, abundant GFP^+^ cells remained in the prostates of mice castrated at 10--12 weeks and harvested at 13- to 14-week chase ([Figures 6](#fig6){ref-type="fig"}B--6D). We also examined whether LRCs resist apoptosis after castration by co-IF analysis of GFP and cleaved caspase-3 in the prostates castrated at 12- to 13-week chase and harvested at 3 days, 1 week, and 2 weeks post castration ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Apoptosis in mouse prostatic luminal cells generally peaks at 3--4 days after castration and persists, at declining levels, in the following 1--3 weeks ([@bib10]). Notably, we did not detect any GFP^+^ LRC cells expressing cleaved caspase-3 in all three experimental settings ([Figure S6](#mmc1){ref-type="supplementary-material"}B), suggesting that castration-induced apoptosis in LRCs is a rare event. To further determine whether the increased number of GFP^+^ LRCs was due to proliferation besides resistance to apoptosis, we performed co-IF of Ki67 and GFP in the above experimental settings. A small number of Ki67^+^ epithelial cells were observed in regressed prostates (e.g., 1-week \[[Figure S6](#mmc1){ref-type="supplementary-material"}C\] or 2-weeks \[[Figure S6](#mmc1){ref-type="supplementary-material"}D\] post castration), but no GFP^+^ Ki67^+^ LRCs were found ([Figure S6](#mmc1){ref-type="supplementary-material"}D), consistent with the dormancy of LRCs. These results collectively demonstrate that luminal LRCs preferentially survive androgen deprivation.Figure 6Luminal LRCs Resist Castration *In Vivo*The Pb-tetVP16-GFP bigenic male mice were castrated at 11, 10, 12, and 12 weeks after chase and analyzed 1 week (A), 4 weeks (B), 1 week (C), and 2 weeks (D) later, respectively. Shown are representative images of urogenital organs and dissected prostate lobes (A), IF of GFP and CK8 in the VP (B--D) and H&E of AP (D) from bigenic mice with or without castration. Quantification of the percentage of GFP^+^ cells in CK8^+^ luminal cell population in different prostate lobes in above experimental castration settings is presented at the bottom. Arrow in (C) indicates a rare GFP^+^CK8^+^ luminal cell. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

Phenotypic Analysis of LRCs Reveals Heterogeneity in Luminal Progenitor Cells {#sec2.8}
-----------------------------------------------------------------------------

Several surface markers have been reported for mouse mammary luminal progenitors, including SCA-1 (or LY6A), CD133, CD117, CD14, CD24 ([@bib30]), NOTCH3 ([@bib16]), and NOTCH1 ([@bib25]). Other than SCA-1 ([@bib3]), similar phenotypic studies in the mouse prostate under physiological (i.e., homeostatic) conditions are generally lacking. CK19 was proposed as a prostate luminal progenitor marker in several studies ([@bib8], [@bib11], [@bib40]) and several SC factors such as BMI1 ([@bib49]), SOX2 ([@bib12]), STAT3 ([@bib29]), and HOXB9 ([@bib5]) have been associated with stem-like prostate (cancer) cells under castration condition. We performed double IF staining of GFP and about a dozen of reported mouse prostate/mammary luminal progenitor markers on prostate tissues collected from bigenic mice chased for 12 weeks and correlated with the marker mRNA levels in RNA-seq ([Figure 7](#fig7){ref-type="fig"}A). Most of these markers were undetectable in normal uncastrated prostates in both formalin-fixed and paraffin-embedded cryosections ([Figure 7](#fig7){ref-type="fig"}A). Consistent with the RNA-seq data ([Figures 5](#fig5){ref-type="fig"}C and [7](#fig7){ref-type="fig"}A), L-GFP^+^ cells expressed relatively abundant CK19 protein compared with L-GFP^−^ cells, although not all CK19^high^ cells were GFP^+^ ([Figures 7](#fig7){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}A). A subset of L-GFP^+^ cells co-expressed SCA-1 at the proximal prostate, and not all SCA-1^+^ cells were GFP^+^ ([Figure 7](#fig7){ref-type="fig"}B), consistent with a recent report that SCA-1 identifies a distinct subset of androgen-independent luminal progenitors in the proximal prostate ([@bib15]). The 12-week-chased L-GFP^+^ cells did not co-localize with BMI1-expresing cells ([Figures 7](#fig7){ref-type="fig"}B and [S7](#mmc1){ref-type="supplementary-material"}A), a rare population that mainly resides in the basal cell layer ([@bib20]), although Bmi1^+^ cells have recently been reported to reside, infrequently, in the luminal layer and mark rare castration-resistant luminal progenitors ([@bib49]). We detected a relatively low and homogeneous expression of NOTCH1 ([Figure 7](#fig7){ref-type="fig"}B), suggesting that, unlike in mammary tissues ([@bib25]), NOTCH1 is not a preferential marker for prostate luminal progenitors. The positive staining of BMI1 and SCA-1 in stromal cells, and cleaved caspase-3 in apoptotic cells shed into the lumen after castration, served as positive control for IF analysis ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Together, these data suggest that prostate luminal progenitors are phenotypically, and, likely, functionally (as reflected by heterogeneous AR expression), heterogeneous.Figure 7Phenotypic Heterogeneity of Luminal LRCs(A) Summary of mRNA (measured in RNA-seq) and protein (measured by IF staining on both frozen and formalin-fixed paraffin-embedded \[FFPE\] sections) expression of the indicated phenotypic markers of the luminal progenitors.(B) Double IF staining of GFP and the indicated markers in FFPE sections of prostate glands harvested from bigenic mice chased for 12 weeks. Boxed regions are enlarged.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

Discussion {#sec3}
==========

Recent studies, employing 2D ([@bib53]) and 3D organoid ([@bib9]) *in vitro* culture systems for human prostate and BrdU pulse-chase ([@bib37]) and lineage-tracing ([@bib4], [@bib22]) techniques for murine prostate, have indicated the existence of luminal progenitors within the luminal cell lineage. In this study, we established a bigenic mouse model to specifically label slow-cycling cells in the prostate epithelium, and further defined luminal LRCs as functional progenitors distinct from bulk luminal cells. These luminal LRCs have the following features: (1) they are relatively dormant and, like BrdU-retaining LRCs ([@bib37]), enriched in the proximal prostate; (2) they display bipotential differentiation ability in both *in vitro* organoid and *in vivo* prostate regeneration assays; (3) they express a progenitor gene signature with preferential expression of neurogenesis- and inflammation-associated genes, and this gene signature is dramatically enriched in treatment-failed PCa; (4) they survive androgen ablation by resisting castration-induced apoptosis and are further enriched in the prostate of castrated mice; and (5) they are phenotypically heterogeneous with only a subset expressing previously reported progenitor markers such as CK19 and SCA-1.

Studying prostatic luminal cells has been challenging due to their low stemness and the current infeasibility of efficient culturing *in vitro*. Prior studies have mainly employed known SC-related surface markers identified in other tissues to dissect the epithelial biology of the prostate. Currently, there is no well-accepted definition for prostate luminal progenitors ([@bib53]), and only a few studies have reported putative phenotypic markers of stem-like luminal cells in humans (i.e., CD38^low^; [@bib18]) and in regressed mouse prostates (e.g., NKX3.1^+^ \[[@bib42]\], SCA-1^+^ \[[@bib15]\], and BMI1^+^ \[[@bib49]\]). The slow-cycling luminal progenitor (i.e., L-GFP^+^) cells, identified here in a marker-independent manner, only partially overlap with a few of previously reported progenitor markers. In fact, most of the markers we analyzed, including CD117, CD14, CD133, STAT3, NOTCH3, CD24, HOXB9, and SOX2, seem to be expressed at too low levels to be reliably detected in the normal mouse prostate. Nevertheless, luminal LRCs appear to generally express low NOTCH1 and high CK19 levels, and a subset of LRCs stains positive for SCA-1. Consistent with a recent report ([@bib49]) showing that BMI1^+^ luminal cells are rarely seen in normal prostate, our LRCs do not co-localize with BMI1^+^ cells. These observations raise a question of whether the mouse prostate, under homeostatic conditions, might have distinct luminal progenitor subsets at varying proliferative states, like the hematopoietic system. For example, our LRCs mainly isolate slow-cycling luminal progenitor cells, while the SCA-1^+^LRCs^−^ might represent fast-proliferating luminal progenitors. Regardless, our study, together with studies from others mentioned above, suggests the presence of multiple luminal progenitor cell populations in the unperturbed mouse prostate. Notably, our present study focuses on normal luminal progenitors; whether these LRCs change their phenotypic marker profiles and then overlap with some of the luminal progenitors (e.g., CARNs and CARBs) previously reported in regressed prostate remains to be determined.

Significantly, the slow-cycling LRCs, like NKX3.1-expressing CARNs ([@bib42]), SCA-1^+^ ([@bib15]), and BMI1^+^ ([@bib49]) luminal progenitors in regressed prostates, are intrinsically resistant to castration, suggesting that the luminal cell layer in normal prostate harbors subsets of naturally androgen-insensitive cells that can survive androgen deprivation. Castration resistance in LRCs could be related to relatively low AR expression, as ∼37% LRCs express low levels of AR protein. Simultaneously or alternatively, castration resistance in LRCs may also be associated with their relative quiescence. In this regard, the L-GFP^+^ cells coordinately underexpress a cohort of positive cell-cycle regulator genes. Detailed dissection of LRCs in castrated prostates is needed to reveal mechanisms of androgen ablation resistance. One potential solution is to perform single-cell RNA-seq analysis to reveal cell-to-cell heterogeneity within the luminal cell compartment under both physiological and castration conditions.

The study of luminal progenitors in the prostate is of great significance to both basic and clinical research. First, luminal cells are the functional units mediating secretory activities and the luminal cell layer is self-sustaining ([@bib4]), indicating the importance of progenitors in maintaining prostate homeostasis and glandular functions ([@bib47], [@bib51]). Second, the luminal layer *in situ* seems to be overall more proliferative ([@bib44], [@bib52]) and murine luminal cells are more susceptible to tumorigenic transformation to generate aggressive tumors ([@bib46]). This raises the possibility of luminal progenitors functioning as preferred cells-of-origin for CRPC. Our current findings that luminal LRCs preferentially survive androgen ablation provide support to this possibility. Third, stem-like luminal cells may function as tumor-propagating cells ([@bib33]), in line with mouse genetic studies ([@bib1], [@bib11]) and with previous report showing that aggressive breast basal-like cancers actually originate from luminal progenitors rather than from basal SCs ([@bib21]). Fourth, while this manuscript was under revision, a study identified a rare castration-resistant luminal progenitor cell population with a Lin^−^/SCA-1^+^/CD49f^med^ phenotype highly enriched in *Pten*-null prostate tumors ([@bib27]). Finally, the luminal progenitor gene expression profile can be linked to advanced and aggressive PCa subtypes ([@bib18], [@bib27], [@bib53]; this study). This notion is further strengthened by the molecular resemblance of our luminal LRCs to recently reported human CD38^low^ prostatic luminal progenitors ([@bib18]), which has been shown to be associated with inflammation and PCa progression with poor outcome. In aggregate, our study presents a comprehensive biological and molecular characterization of slow-cycling prostate luminal progenitors. Further studies on the functional roles of luminal LRCs in tumorigenesis, and the molecular mechanisms that regulate their homeostasis and dormancy, may yield new predictive markers and therapeutic targets for aggressive CRPC.

Experimental Procedures {#sec4}
=======================

General procedures in producing and propagating transgenic animals have been described previously ([@bib34]). All animal work was performed under the University of Texas MD Anderson Cancer Center and Roswell Park Cancer Institute IACUC approved protocols. Immunostaining was performed on either paraffin-embedded or OCT frozen sections. The mouse prostate tissues were enzymatically digested with collagenase IA and Dispase, followed by FACS analysis using the BD Aria (BD Biosciences).

Additional experimental procedures are detailed in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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